DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
André F, Ciruelos EM, Juric D. et al.
Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC).
Ann Oncol 2020;
31 (Suppl. 04) S1142-S1215
doi:10.1016/annonc/annonc325
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.